glp-1 inflammatory bowel disease Glucagon-like peptide-1 (GLP-1) receptor agonists in disease: mechanisms, clinical implications, and therapeutic potential GLP-1 | Summary

demonstrated that weekly administration of either GLP-1 RA semaglutide or dulaglutide produces a rapid, substantial and dose-dependent reduction in EAT thickness [37], that may bring to a reduction in the pro-inflammatory stimuli

The serum ChE activities of the calves and of those handling the animals were within normal values (Henriksson et al., 1971)

Higher risk groups include: People starting GLP-1 medicines for the first time People whose dose is increased too quickly People who eat large, oily, or very sweet meals People with type 2 diabetes using insulin or sulfonylureas People with previous pancreatitis People with gallstones or gallbladder disease People with severe digestive disorders People with gastroparesis People with kidney disease People with dehydration risk People with diabetic retinopathy People with a personal or family history of medullary thyroid carcinoma People with Multiple Endocrine Neoplasia syndrome type 2 People with active mood disorders or suicidal thoughts People planning surgery or procedures under anaesthesia Patients With Diabetes Vs Non-Diabetic Users People with diabetes may use GLP-1 medicines to improve blood sugar control and support weight management

doi: 10.1080/00325481.2022.2051366